Abstracts tagged "Quality Indicators"

Abstract Number: 0574 • ACR Convergence 2020
Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
Katherine Pryor¹, Chang Xu¹, Jamie Collins¹, Karen Costenbader² and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine/chloroquine (HCQ/CQ) is considered to be the backbone of systemic lupus erythematosus (SLE) care. Differences in receipt of HCQ/CQ may exacerbate disparities in adverse…
Abstract Number: 0603 • ACR Convergence 2020
Multisite Study of the Impact of COVID-19 Era Telemedicine Expansion on Reduction in No-Show Rates
Christie Bartels¹, David Gazeley², Ann Rosenthal³, Sancia Ferguson⁴, Edmond Ramly⁵, Monica Messina⁶ and Douglas White⁷, ¹University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Milwaukee, WI, ⁴University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Oakland, CA, ⁵University of Wisconsin School of Medicine and Public Health, Department of Family Medicine and Community Health;, Madison, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine, Rheumatology Division, Madison, WI, ⁷Gundersen Health System, Onalaska, WI
Background/Purpose: The COVID-19 pandemic led to rapid expansion of telemedicine in all fields, including rheumatology. We hypothesized that increased use of telemedicine would reduce no-show…
Abstract Number: 1586 • ACR Convergence 2020
Rheum Service: Comprehensive Virtual Care During COVID-19
Stephanie Gottheil¹ and Joseph Carson¹, ¹London Rheumatology, London, ON, Canada
Background/Purpose: During COVID-19, patients require timely access to rheumatologists while adhering to physical distancing guidelines. In this quality improvement project, we developed a comprehensive virtual…
Abstract Number: 1588 • ACR Convergence 2020
A Quality Improvement Project to Improve Bone Densitometry Ordering in Adult Patients on Chronic Glucocorticoids
Katherine Kaufman¹, Philip Chu¹, Mithu Maheswaranathan¹, Andrew Johannemann¹, D Ryan Anderson¹, Isaac Smith¹, Akrithi Udupa¹, Mary Buckley¹, Laura Cannon¹, Rachel Randell¹ and David Leverenz¹, ¹Duke University, DURHAM, NC
Background/Purpose: The 2017 ACR guideline for glucocorticoid-induced osteoporosis (GIOP) recommends DXA testing in patients aged ≥40 years on chronic glucocorticoids. We performed a quality improvement…
Abstract Number: 278 • 2019 ACR/ARP Annual Meeting
Improving a SLE-Quality Indicator Tool in an Outpatient Tertiary Care Setting
Jun Chu¹, Elaine Poncio ², Yenealem Temesgen-Oyelakin ², Michael Davis ³, Isabel Ochoa-Navas ², Sarthak Gupta ⁴, Zerai Manna ², Marquis Chapman ¹, Eileen Chu ⁵, Aidan Donnellan ⁶ and Sarfaraz Hasni ⁷, ¹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, ²NIAMS/NIH, Bethesda, ³NIAMS/NIH, Bethesda, MD, ⁴Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, ⁵National Institutes of Health, Derwood, MD, ⁶National Institutes of Health, Bethesda, ⁷NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: The care for patients with lupus is complex as they may exhibit multiple concomitant medical and socioeconomic issues. To address all their needs according…
Abstract Number: 1192 • 2019 ACR/ARP Annual Meeting
Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital
Hiroki Ozawa¹, Sho Fukui ¹, Genki Kidoguchi ¹, Takehiro Nakai ², Satoshi Kawaai ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a common, preventable and treatable complication of glucocorticoid therapy. We defined quality indicator (QI) for GIOP and took a hospital-wide…
Abstract Number: 1178 • 2018 ACR/ARHP Annual Meeting
Patients’ and Healthcare Professionals’ Resource Preferences for a Knowledge Translation Toolkit for Hip and Knee Replacement Rehabilitation
Marie Westby¹, Cheryl L. Koehn², Sheila Kerr³ and Alison Hoens⁴, ¹Centre for Hip Health and Mobility, Vancouver, BC, Canada, ²Arthritis Consumer Experts, Vancouver, BC, Canada, ³Patient Advisor, Vancouver, BC, Canada, ⁴Physical Therapy, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Widely varying rehabilitation practices for total joint replacement (TJR) for hip and knee osteoarthritis (OA) contribute to inconsistent patient outcomes and satisfaction. Informed by…
Abstract Number: 2960 • 2018 ACR/ARHP Annual Meeting
Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment
Claire Barber¹, Diane Lacaille², Peter Faris³, Dianne P. Mosher⁴, Steven J. Katz⁵, Joanne Homik⁶, Jatin Patel⁷, Sharon Zhang⁷, Cheryl Barnabe⁸, Glen Hazlewood⁹, Vandana Ahluwalia¹⁰, Natalie J. Shiff¹¹, Vivian P. Bykerk¹², Marinka Twilt¹³, Susanne Benseler¹⁴, Jennifer Burt¹⁵ and Deborah A. Marshall¹⁶, ¹Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Arthritis Research Canada/University of British Columbia, Medicine/Rheumatology, Richmond, BC, Canada, ³Alberta Health Services, Alberta, AB, Canada, ⁴Med, University of Calgary, Calgary, AB, Canada, ⁵Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸Medicine, University of Calgary, Calgary, AB, Canada, ⁹Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada, ¹⁰William Osler Health Center, Brampton, ON, Canada, ¹¹University of Florida, Gainesville, FL, ¹²Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ¹³University of Calgary, Calgary, AB, Canada, ¹⁴Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁵St. Clare's Mercy Hospital, Eastern Health, St. John's, NF, Canada, ¹⁶Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Early diagnosis, treatment and ongoing care are critical to optimize RA outcomes. The purpose of the study was to evaluate key elements of RA…
Abstract Number: 1085 • 2017 ACR/ARHP Annual Meeting
Application of Lupus Nephritis Quality Measures to Understand Gaps in Care for SLE
Lisa Gaynon¹, Maria Dall'Era², Patricia P. Katz², Lindsey A. Criswell², Cristina Lanata², Laura Trupin³, Charles G. Helmick⁴ and Jinoos Yazdany³, ¹Internal Medicine, California Pacific Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: In 2012, the ACR released guidelines for monitoring and treatment of lupus nephritis (LN), but studies have yet to evaluate adherence to these recommendations.…
Abstract Number: 1593 • 2017 ACR/ARHP Annual Meeting
Development of Quality Indicator Set of Systemic Lupus Erythematosus in Japan
Nobuyuki Yajima¹, Ken-ei Sada², Shingo Fukuma³, Yasushi Tsujimoto⁴, Sayaka Shimizu³, Kakuya Niihata⁵, Tsuneyo Mimori⁶, Yoshiya Tanaka⁷, Tsutomu Takeuchi⁸, Mayumi Sugiura⁹, Hitoshi Kohsaka¹⁰, Naoto Tamura¹¹, Masataka Kuwana¹², Hideto Kameda¹³, Asano Yoshihide¹⁴, Teruhisa Azuma¹⁵, Toshihiro Matsui¹⁶, Katsuya Suzuki¹⁷, Ryo Takahashi¹, Shunichi Fukuhara³ and Tatsuya Atsumi¹⁸, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine and Public Health, Kyoto, Japan, ⁴Department of Nephrology and Dialysis, Kyoritsu Hospital, Hyogo, Japan, ⁵Division of Clinical Epidemiology, Fukushima Medical University, FUKUSHIMA, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁹Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medical sciences, Nagoya, Japan, ¹⁰Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ¹¹Rheumatology, Juntendo University, Tokyo, Japan, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ¹⁴Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ¹⁵Satellite for Teaching And Research in General Medicine, Fukushima Medical University, Fukushima, Japan, ¹⁶Department of Lifetime Clinical Immunology Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan, ¹⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: A QI set for systemic lupus erythematosus (SLE) was developed in the United States. However, this does not necessarily conform to the Japanese medical…
Abstract Number: 21 • 2017 Pediatric Rheumatology Symposium
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Emily A. Smitherman¹, Adam Furnier², Janalee Taylor³, Mary Beth Burns⁴, Hermine Brunner⁵ and Esi Morgan¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: Childhood-onset SLE (cSLE) leads to poor health outcomes, including cardiovascular and bone health, due to high rates of potentially devastating disease complications and medication…
Abstract Number: 1404 • 2016 ACR/ARHP Annual Meeting
Systematic Review and Appraisal of Quality Measures for Inflammatory Arthritis
Matthew Cooper¹ and Claire E H Barber², ¹University of Calgary, Calgary, AB, Canada, ²Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Quality measures are metrics health professionals can monitor to improve care delivery and patient outcomes. To be measurable they must include a specified numerator,…
Abstract Number: 2247 • 2016 ACR/ARHP Annual Meeting
REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States
Bruce Kirkham¹, Estee Chan², Alexandra Vincent² and Alison Elliott³, ¹Rheumatology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Market Access Directorate, Roche Products LTD UK, Welwyn Garden City, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) has differing therapeutic outcomes, with resulting differences in function and quality of life. Little is known about the effects of disease…
Abstract Number: 368 • 2015 ACR/ARHP Annual Meeting
The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital
Masei Suda¹, Masato Okada¹, Yasuhiro Suyama², Mitsumasa Kishimoto¹ and Tokutaro Tsuda¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Rheumatology, JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most clinically significant side effects of glucocorticoid use, and the prevention of GIOP has become more important…
Abstract Number: 999 • 2015 ACR/ARHP Annual Meeting
Development of Quality Indicators for Hip and Knee Arthroplasty Rehabilitation
Marie Westby¹, Deborah Marshall², Jane Squire Howden³ and C. Allyson Jones⁴, ¹School of Public Health, University of Alberta, Edmonton, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Edmonton Musculoskeletal Centre, Edmonton, AB, Canada, ⁴Physical Therapy, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rehabilitation before and after total hip (THA) and knee arthroplasty (TKA) surgery has been shown to decrease pain and impairment, and improve mobility, activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].